Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04413279
Other study ID # The DIERKER Study
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date August 1, 2020
Est. completion date July 1, 2021

Study information

Verified date April 2022
Source Eye Surgeons of Indiana
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the benefit of treatment with a physician administered intracanalicular dexamethasone insert in evaporative dry eye disease (DED) patients with meibomian gland disfunction (MGD) and underlying inflammation undergoing LipiFlow Thermal Pulsation.


Description:

This prospective, open-label, single-center, non-randomized, investigator-sponsored clinical study seeks to investigate the benefit of managing patients with DED secondary to MGD with a sustained release intracanalicular dexamethasone (0.4 mg) insert in addition to LipiFlow Thermal Pulsation compared to LipiFlow Thermal Pulsation alone. In addition, this study will evaluate the ease of Dextenza insertion and the patient preference for therapy. After screening a given patient for inclusion and exclusion criteria, and gaining informed consent, each eye will undergo LipiFlow Thermal Pulsation on the same day. The most symptomatic eye will be selected to receive DEXTENZA® insertion on the day of the procedure (study eye), while the other eye will be assigned to a receive a sham punctum dilation (control eye). If there is no obvious symptomatic difference, the right eye will receive the intracanalicular insert. Per patient, the study period will last for approximately 12 weeks after the LipiFlow procedure, consisting of one screening visit, one treatment v4isit and 3 post-procedure follow-up visits (week 1, week 4 and week 12). At week 1, week 4 and week 12, primary and secondary endpoints will be assessed alongside standard-of-care procedures. Adjusting for enrollment period, the study will last a total of approximately 4 months.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date July 1, 2021
Est. primary completion date July 1, 2021
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: A patient's study eye must meet the following criteria to be eligible for inclusion in the study: - 18 years of age or older - Evaporative DED with MGD and clinically significant inflammation - Willing and able to comply with clinic visits and study related procedures - Willing and able to sign the informed consent form Exclusion Criteria: A patient who meets any of the following criteria will be excluded from the study: - Patients under the age of 18. - Pregnancy (must be ruled out in women of child-bearing age with pregnancy test) - Active infectious systemic disease - Active infectious ocular or extraocular disease - Altered nasolacrimal flow of either acquired, induced, or congenital origin - Hypersensitivity to dexamethasone - Patient being treated with either topical, oral, or intravenous steroids - Patients with severe disease that warrants critical attention, deemed unsafe for the study by the investigator

Study Design


Intervention

Procedure:
LipiFlow Thermal Pulsation
To manage patients with dry eye disease secondary to MGD
Drug:
Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal Pulsation
to investigate the benefit of managing patients with DED secondary to MGD with a sustained release intracanalicular dexamethasone (0.4 mg) insert in addition to LipiFlow Thermal Pulsation

Locations

Country Name City State
United States Eye Surgeons of Indiana Indianapolis Indiana

Sponsors (2)

Lead Sponsor Collaborator
Eye Surgeons of Indiana Ocular Therapeutix, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in meibomian gland scores (expressibility and quality) As measured on a grading scale 1 to 4 and graded by the physician Assessed at Baseline, Week 1, Week 4 and Week 12
Primary Patient preference for As measured by COMTOL Survey Assessed at Week 12
Secondary Mean change in MMP-9 As measured by InflammaDry Assessed at Baseline, Week 1, Week 4 and Week 12 Visit
Secondary Mean change in ocular surface staining As measured by sodium fluorescein and lissamine green Assessed at Baseline, Week 1, Week 4 and Week 12 Visit
Secondary Mean change in tear break-up time (TBUT) As measured by TBUT testing Assessed at Baseline, Week 1, Week 4 and Week 12 Visit
Secondary Mean change in tear osmolarity As measured by TearLab Assessed at Baseline, Week 1, Week 4 and Week 12 Visit
Secondary Mean change in DEQ-5 As measured by DEQ-5 Questionnaire (Dry Eye Questionnaire. The DEQ-5 is comprised of 5 items: frequency of watery eyes, discomfort, and dryness (0-4 scale) and late day discomfort and dryness intensity (0-5 scale). Higher numbers indicate more severe symptoms. Assessed at Baseline, Week 1, Week 4 and Week 12 Visit
Secondary Mean change in Best-corrected Visual Acuity (BCVA) As measured by ETDRS chart Assessed at Baseline, Week 1, Week 4 and Week 12 Visit
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04425551 - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction N/A
Not yet recruiting NCT06379685 - Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface. Phase 1
Recruiting NCT04701086 - 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis N/A
Active, not recruiting NCT03697876 - Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel Phase 1
Terminated NCT02815293 - Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye Phase 3
Completed NCT02910713 - Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation N/A
Completed NCT04104997 - A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers Phase 1
Recruiting NCT02595606 - 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Phase 4
Completed NCT01711424 - An Observational Study of OPTIVE PLUS® for the Treatment of Dry Eye Disease N/A
Completed NCT01202747 - Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction Phase 2/Phase 3
Completed NCT01015209 - Safety and Tolerability of Chitosan-N-acetylcysteine Eye Drops in Healthy Young Volunteers Phase 1
Completed NCT00969280 - Acupuncture for Dry Eye Syndrome Phase 3
Completed NCT00756678 - Efficacy and Acceptability of Two Lubricant Eye Drops Phase 4
Completed NCT00739713 - Effects of Sea Buckthorn Oil on Dry Eye N/A
Completed NCT01496482 - Comparison of Evaporimetry With the Established Methods of Tear Film Measurement N/A
Completed NCT00349440 - Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy Phase 4
Completed NCT00370747 - Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome Phase 2
Completed NCT05162261 - to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction N/A
Completed NCT02871440 - A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evaporative Dry Eye Phase 3
Completed NCT05042960 - Computer Screen Properties Study N/A